Multiple Myeloma

Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics

Evolving Treatment Strategies in Transplant-Ineligible NDMM: Expert Insights From CEPHEUS, IMROZ and BENEFIT

Advancing Frontline Therapy in Transplant-Eligible Myeloma and Emerging Trends in Smoldering Myeloma Management

Managing Early Relapse in Transplant-Eligible MM and the Influence of Clonal Evolution

Why a Patient With Multiple Myeloma Might Decline Stem Cell Transplant: Mansi Shah, MD

How Transplant, CAR T, and Bispecifics Fit Into Myeloma Care: Mansi Shah, MD

Balancing Timing of ASCT: Insights on Delayed Transplantation and Long-Term Treatment Outcomes

Tailoring Maintenance Therapy by Patient Risk: Lenalidomide Alone vs Combination Approaches

Self-Administered Subcutaneous Isatuximab May Ease Multiple Myeloma Treatment Burden: Xavier Leleu, MD, PhD

Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD